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Abstract
Background: QuantiFERON-TB Gold In-Tube® (QFT-GIT) test is used for the diagnosis of latent tuberculosis (TB)
infection. Besides, QFT-GIT test could allow tracking changes in immune response among TB patients and their contacts.
In high TB burden settings, reports on QFT-GIT conversions and reversions among TB patients and their contacts are
limited. As part of a major project to study immune responses to TB infection, we investigated QFT-GIT test conversions
and reversions among smear positive pulmonary TB patients and their household contacts over 12 months.
Methods: We followed a total of 107 HIV negative participants (33 patients and 74 contacts) in Addis Ababa. We did
QFT-GIT test at baseline and 12 months later according to the manufacturer’s instructions.
Results: At baseline, 25/33 (75.8%) of the patients and 50/74 (67.6%) of the contacts were QFT-GIT positive. At 12 months,
2 more patients (1 test negative and 1 indeterminate) became test positive. Besides, 11/24 (45.8%) test negative contacts
became positive. Only one patient and one contact who were test positive at baseline became test negative 12 months
later. At 12 months, the proportions of QFT-GIT test positives for patients and contacts were, therefore, 78.8% and 81.1%,
respectively. Among contacts, the proportion of QFT-GIT test positives at 12 months was significantly higher compared
to the corresponding proportion at baseline (McNemar, p = 0.006); similarly, the median IFN-γ response significantly
increased at 12 months compared with the baseline level (Wilcoxon matched-pairs signed rank test, p = 0.01). Patients,
however, had comparable median IFN-γ levels at baseline and 12 months later (p = 0.56).
Conclusion: Nearly half of QFT-GIT negative household contacts at baseline became positive at 12 months. This suggests
that repeated screening of QFT-GIT negative contacts may be needed for epidemiological studies and interventions of
latent TB in an endemic setting. A large longitudinal study may be needed to confirm our observations.
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Background
Tuberculosis (TB) remains a serious public health prob-
lem, especially in low income countries, despite the glo-
bal effort to tackle it for the past 20 years. In 2012 alone,
there were 8.6 million incident cases and 1.3 million
deaths [1]. Early detection and proper treatment of TB
cases are the main strategies to control TB [2]. However,
delayed diagnosis of TB patients and transmission to
contacts is a major challenge. Although infection rates
are high, the majority of infected contacts do not pro-
gress to active TB. The risk of progression to active TB
is greatest in the first 2-5 years following infection [3,4].
Preventive therapy among household contacts of TB pa-
tients has been the practice in most low prevalence coun-
tries as one of the key strategies to eliminate TB. However,
in TB endemic countries, the prevalence of latent TB is
high and preventive therapy is limited to those individuals
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with HIV infection and children <5 years of age with an
adult household contact [5]. Tuberculin skin test (TST) has
been routinely used to screen latent TB; however, it has
poor specificity among BCG vaccinated populations [6,7].
Currently, two T-cell based interferon gamma release as-
says (IGRAs) are being used for the diagnosis of latent TB
infection and surveillance of new infections. The high spe-
cificity of IGRAs to TB infection even among BCG vacci-
nated population [7,8] makes them more appealing.
QuantiFERON-TB Gold In-Tube® (QFT-GIT) test is one
of the two commercialized IGRA tests being used for the
diagnosis of latent TB infection. Conversions and rever-
sions are reported to be common in studies from low TB
prevalence countries [9-11]. Conversions indicate recent
infections with increased risk of progression [12] whereas
reversions may indicate bacterial clearance. There is lim-
ited information regarding conversions and reversions of
QFT-GIT test results among pulmonary TB patients and
their household contacts in high TB burden countries.
Here, for the first time in Africa, we report conversions
and reversions among TB patients and their household
contacts over 12 months.
Methods
Study setting and population
This study was conducted as part of a large follow-up
study investigating the role of humoral and cell mediated
immune protection during M. tuberculosis infection
among a human population in Addis Ababa. Addis
Ababa has a population of 2.6 million [13].
TB patients are primarily treated at health centers. Out
of 24 health centers with established Directly Observed
Treatment, Short course (DOTS) services, 7 health centers
(Kotebe, Akaki, Kazanchis, Bole, Shiro Meda, Woreda 7
and Teklehaymanot) were selected for the study. From
April to December 2012, smear positive pulmonary TB
patients were recruited before treatment initiation. The
diagnosis of smear positive pulmonary TB was made when
at least two out of three consecutive sputum smear exami-
nations were positive for acid fast bacilli. Subsequently,
successful growth on Lowenstein-Jensen solid media was
used to confirm diagnosis. Patients were treated with
anti-TB drugs for 6 months according to the national
guideline [5]. Household contacts living in the same
house with smear positive TB patients were screened
for TB using clinical assessment and chest x-ray. AFB
and culture was done for those with productive cough.
Contacts donated blood samples within 1 to 7 days fol-
lowing diagnosis of TB among patients. No prophylactic
treatment was given to contacts without evidence for TB.
Patients were assessed for any concurrent illnesses includ-
ing medication side effects. Contacts were reassessed at 6
months and were also encouraged to report any illness
between follow-up visits. All participants were adults
(18-60 years). HIV testing was done according to the na-
tional guideline [14] and only HIV negative patients and
contacts were included.
Sample collection and ELISA
QFT-GIT test was performed according to the manufac-
turer’s instructions (Cellestis, Carnegie). Briefly, 1 ml of
whole blood was drawn into each of the three tubes sup-
plied by the manufacturer. Each tube contained no antigen
(negative control), PHA (positive control) or peptides of
the M. tuberculosis antigens Early Secretory Antigenic
Target 6 (ESAT-6), Culture Filtrate Protein 10 (CFP-10)
and TB 7.7 (p4). Blood specimens from all health centers
were transported and incubated at Armauer Hansen
Research Institute (AHRI) laboratory within 4-6 hours of
collection. The tubes were incubated for 24 hours at 37°C,
centrifuged at 3000 rpm for 15 minutes and supernatants
stored at -80°C until enzyme-linked immunosorbent assay
was done to measure IFN-γ production. Calculation of re-
sults was done using QuantiFERON ®-TB Gold analysis
software version 2.62 (Cellestis, Carnegie, Australia). A
positive test result was determined at a cut-off value of
0.35 IU/ml, according to the manufacturer’s recommenda-
tion. Standard operating procedures as well as company’s
instructions were followed during sample collection,
incubation, storage and IFN-γ measurement to minimize
potential sources of variability.
Data analysis
QFT-GIT test positive proportions were calculated.
McNemar test was used to compare test positive propor-
tions at baseline and 12 months later. Mann-Whitney
test was used to compare IFN-γ response among con-
tacts and patients. Wilcoxon matched-pairs signed rank
test was used to investigate changes in IFN-γ levels at 12
months compared to baseline levels. GraphPad Prism
version 6 (GraphPad Software, La Jolla California USA,
http://www.graphpad.com) was used to analyze the data.
A p-value less than 0.05 was considered statistically
significant.
Ethics statement
The study protocol was approved by the Institutional Re-
view Board of Aklilu Lemma Institute of Pathobiology,
AHRI/ALERT Ethics Review Committee, The National
Health Research Ethics Review Committee from Ethiopia
and the Regional Committees for Medical Research Ethics,
South East Norway (Regionale komiteer for medisinsk og
helsefaglig forskningsetikk sør-øst) from Norway. Written
informed consent was obtained from each participant.
Results
A total of 107 HIV negative participants (33 smear posi-
tive pulmonary TB patients and 74 household contacts)
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were followed over one year. The median age was 28 years
(IQR: 23-42 years). Patients (median age of 27 years) and
contacts (median age of 29 years) had comparable median
age. Overall, females constituted 55.7% of the study partic-
ipants. There were more females among contacts (60.8%)
compared to patients (43.8%). However, the difference was
not statistically significant (X2 = 2.6, p = 0.11).
The median duration of cough among patients before
treatment was 8 weeks (IQR: 4-29 weeks). Among con-
tacts, 27 (36.5%) reported sleeping on the same bed and
18 (24.3%) in the same room with the patient. The rest
were sleeping in a different room in the same house. No
significant difference was observed between proximity of
sleeping and infection. On average, contacts reported a
median contact duration of 12 hours (IQR: 9-12 hours)
per day with the patient.
At 6 months, all patients were declared cured based
on sputum conversion and clinical assessment. Among
household contacts, two progressed to active TB: one of
these contacts was diagnosed as smear positive at 6
months and the other contact was diagnosed as smear
negative and culture positive at 12 months. At baseline,
25 (75.8%) of the patients were QFT-GIT positive, one
was indeterminate and 7 were QFT-GIT negative. Simi-
larly, 50 (67.6%) of the contacts were QFT-GIT positive
and the rest were QFT-GIT negative.
With regard to conversions and reversions, after 12
months, only one patient with a negative QFT-GIT test re-
sult and another patient with indeterminate result became
positive. Besides, only 1/25 (4%) QFT-GIT positive pa-
tients at baseline became QFT-GIT negative at 12 months.
Among contacts, 11/24 (45.8%) of QFT-GIT negative par-
ticipants became positive. On the other hand, only 1/50
(2%) QFT-GIT positive contacts became negative. In total,
60 (81.1%) of the contacts were QFT-GIT positive at 12
months. The two contacts who progressed to active TB
were QFT-GIT negative at baseline but both were QFT-
GIT positive at diagnosis of active TB.
Among household contacts, the proportion of QFT-
GIT positive was significantly higher at 12 months
compared to the proportion at baseline (McNemar,
p = 0.006); however, no significant difference was ob-
served among patients (McNemar, p = 1.00) (Table 1).
Among household contacts, the median level of IFN-
γ significantly increased at 12 months compared to
baseline levels (Wilcoxon matched pairs signed rank
test, p = 0.01). Patients had comparable median IFN-γ
levels at baseline and 12 months later (p = 0.56)
(Figure 1). With regard to the proportion of QFT-
GIT positives, there was no statistically significant
difference between contacts and patients both at
baseline (Mann-Whitney, p = 0.35) and 12 months
later (Mann-Whitney, p = 0.98). Similarly, the median
levels of IFN-γ among patients and contacts
were comparable both at baseline and 12 months
later (Figure 2). Among 11 contacts with conversions,
9 had IFN-γ level above 1 IU/ml whereas only 2 had
just above 0.5 IU/ml indicating a strong IFN-γ re-
sponse among converters (Table 2, Additional file 1).
Discussion
The use of QFT-GIT test in longitudinal studies could
allow tracking changes in immune response over time.
In this study, we investigated conversions and reversions
of QFT-GIT test results among TB patients and their
household contacts in a high TB burden setting. The key
findings of this study included: (a) a very low rate of re-
version both in patients and contacts, and (b) a high rate
of conversion among household contacts.
At baseline, a very high proportion of contacts were
QFT-GIT positive in this study. However, in other high
burden settings, similar studies [15,16] reported a lower
prevalence (54-59%) of latent TB infection among house-
hold contacts. This difference might be attributable to the
differences in the degree of exposure. Previously, a 63.7%
prevalence of latent TB infection was diagnosed among
healthy adult pastoralists in Afar Region [17] suggesting
that there is already a high rate of latent TB infection
among the population. Besides, a long diagnostic delay
among TB patients is a major problem in Ethiopia [18]
and infection from recent exposure might account for the
high prevalence of latent TB among household contacts in
the study area.
Previous studies reported different rates of QFT-GIT
test conversions and reversions among household con-
tacts and those with no obvious contact history. Compar-
able to our finding, a study from Uganda reported a TST
conversion rate of 41% among household contacts over a
year [19]. Similarly, another study from India reported a
higher QFT-GIT test conversion rate compared to rever-
sions [16]; however, they also reported a high reversion
rate unlike our findings. Contrary to our findings, other
studies reported that reversions were found to be more
common compared to conversions [10,20]. For example, a
Table 1 Comparison of QFT-GIT test results at baseline
and 12 months among contacts and patients
Patients Contacts
n(%) n(%)
Baseline 12 months Baseline 12 months
QFT-GIT-negative 7 (21.9*) 6 (18.8*) 24 (32.4) 14 (18.9)
QFT-GIT-positive 25 (78.1*) 26 (81.2*) 50 (67.6) †60(81.1)
McNemar, p-value 1.00 0.006
*One patient with indeterminate result at baseline was excluded from
the denominator.
†One QFT-GIT positive contact at baseline became negative at 12 months and
hence the total QFT-GIT positive contacts at 12 months were 60 instead of
61 (50 + 11).
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study from the US among HIV infected individuals whose
contact history was unknown reported that a third of
QFT-GIT test positive individuals became negative at 24
months and the conversion rate was only 9% [20]. An-
other study among German health care workers reported
a low rate of conversion (1.9%) compared to the rate of re-
version (33.3%) [10]. Unlike the participants in these two
studies, our study participants were household contacts of
smear positive pulmonary TB patients and some of them
could be in the incubation period at baseline with subse-
quent test conversions. Besides, in Ethiopia where the esti-
mated prevalence of smear positive pulmonary TB is 108
per 100,000 population [21], multiple exposures to pul-
monary TB patients are expected and during the follow-
up period, some of our contacts might have been exposed
out of home and infected. This could partly explain the
high conversion and the low reversion rates. Other factors
including geographical [22] and M.tuberculosis strain [23]
variations are also reported to be associated with varia-
tions in IFN-γ response and hence may partly explain the
difference observed across settings.
In pulmonary TB patients, reversions and conversions
were very low. Besides, the baseline and 12 months median
levels of IFN-γ were comparable. However, studies from
The Gambia [24], Japan [25] and South Korea [26] reported
high reversion rates following treatment completion.
Reasons for such variations are not clear from the
current study. However, in high burden settings like
Ethiopia, IFN-γ could possibly be boosted from casual
contact with other TB patients. Supporting this asser-
tion is the fact that during the 6 month treatment
period, TB patients come in contact with each other
without restriction at DOTS clinics. Besides, the low re-
version rate in our study could be due to stimulation of
the immune system by persistent M.tuberculosis infec-
tion as suggested previously [27]. Although the sample
size is small, our result confirms that QFT-GIT may not
be useful for treatment monitoring among TB patients
in high burden setting as previously reported [28].
In our study, 2 household contacts who were QFT-GIT
test negative at baseline progressed to active pulmonary
TB. Although the data is small, this contradicts the sug-
gestion that IFN-γ release assays could potentially iden-
tify those with a high risk of progression among latently
infected individuals [16]. Converters could be important
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Figure 1 Comparison of median levels of IFN-γ at baseline and 12 months later among patients (n = 32) and contacts (n = 74). Wilcoxon
matched-pairs signed rank test was used to analyze the data. Each filled circle represents a participant and the horizontal solid lines represent
medians. The median level of IFN-γ among contacts was significantly increased at 12 months compared to baseline level but among patients,


























Figure 2 Comparison of the median levels of IFN-γ between patients (n = 32) and contacts (n = 74) at baseline and 12 months.
Mann-Whitney test was used to analyze the data. Each filled circle represents a participant and horizontal solid lines represent medians. There
was no statistically significant difference in the median levels of IFN-γ between patients and contacts both at baseline and 12 months later.
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study from South Africa compared the risk of progres-
sion between converters and persistent QFT-GIT nega-
tive adolescents and found a significantly increased risk
of progression among converters. Our finding suggests
the need for repeated screening of QFT-GIT negatives
especially if prophylactic anti-TB treatment is offered for
latent TB infection based on QFT-GIT test result.
This study has revealed important findings. However,
the results of this study need to be interpreted in view of
its limitations. We were not able to compare QFT-GIT
test results with TST results since we deliberately omitted
TST for the larger cohort to avoid possible sensitization of
immune responses. However, we believe this may not
affect our findings as many studies have reported a good
degree of agreement between these two tests and QFT-
GIT is more specific to TB infection compared to TST.
QFT-GIT test variability could be a potential source of
bias but we strictly followed the company’s recommen-
dation during sample collection, incubation, sample
storage and ELISA and hence the impact of such vari-
ability is expected to be minimal. Almost all converters
had IFN-γ levels much higher than the cut-off value and
hence they are most likely true converters. The other
limitation of this study is the exclusion of children as
well as those with immunosuppressive conditions and
therefore, the findings of this study may not be general-
ized to these groups.
Conclusion
Conversions are common among household contacts in
this study; however, reversions were rare both among
patients and contacts. Therefore, for epidemiologic stud-
ies and interventions of latent TB, repeated screening of
QFT-GIT negative contacts may be needed to diagnose
TB infection in a high TB burden setting. A larger
follow-up study including children and those with im-
munosuppressive conditions could generate more evi-
dence on the rate of conversions and reversions as well
as the risk of progression to active TB among different
groups (converters, persistent QFT-GIT positives and
persistent QFT-GIT negatives).
Additional file
Additional file 1: Levels of IFN-γ at baseline and 12 months later
among 24 contacts with baseline QFT-GIT negative results. Wilcoxon
matched-pairs signed rank test was used to analyze the data. Each filled
circle represents a participant. Solid lines joining filled circles indicate
the changes in the level of IFN-γ over 12 months in each participant.
The broken horizontal line represents the cut-off for classifying
participants as positive (greater or equal to the cut-off) and negative
(less than the cut-off). Almost all converters had IFN-γ levels much higher
than the cut-off value.
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Table 2 Levels of IFN-γ at baseline and 12 months later
among QFT-GIT negative contacts at baseline
Participant IFN-γ (IU/ml) IFN-γ (IU/ml) QFT-GIT result
at 12 monthsat baseline at 12 months
Non-converters
1 0.00 0.05 Negative
2 0.02 0.02 Negative
3 0.12 0.21 Negative
4 0.03 0.03 Negative
5 0.00 0.34 Negative
6 0.00 0.00 Negative
7 0.00 0.04 Negative
8 0.00 0.08 Negative
9 0.00 0.03 Negative
10 0.06 0.17 Negative
11 0.00 0.00 Negative
12 0.01 0.00 Negative
13 0.00 0.03 Negative
Converters
14 0.19 0.53 Positive
15 0.28 0.57 Positive
16 0.21 1.15 Positive
17 0.00 2.19 Positive
18 0.02 2.27 Positive
19 0.03 2.47 Positive
20 0.01 2.68 Positive
21 0.08 4.31 Positive
22 0.02 4.52 Positive
23 0.04 5.54 Positive
24 0.00 8.94 Positive
Contacts from number 1 to 13 (n = 13) were QFT-GIT negative both at baseline
and at 12 months with low IFN-γ response whereas contacts from number
14 to 24 (n = 11) were negative at baseline but became positive at 12 months.
Nine of the 11 contacts with QFT-GIT test conversions had high IFN-γ response
at 12 months whereas 2 (number 14 and 15) of them had IFN-γ values close
to the cut-off (0.35).
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